On Friday evening, November 20, 2026, Capricor Therapeutics, Inc. (NASDAQ: CAPR) closed regular trading quietly at $7.59 (+0.80%), two days ahead of its Sunday, November 22 PDUFA decision deadline for deramiocel (BLA 125842), an experimental cell therapy for Duchenne muscular dystrophy (DMD). Minutes after 6:00 PM ET, the floor vanished: CAPR plunged -80.37% (-$6.10) in after-hours trading to $1.49 (cutting its market capitalization from $441.3 million to $86.6 million across 58.14 million shares).

The trigger was an extraordinary, pre-deadline rejection by the U.S. Food and Drug Administration (FDA), accompanied by a rare public statement (“Statement on Deramiocel BLA for Duchenne Muscular Dystrophy — FDA determined that the available evidence does not meet the evidentiary standard required for approval”, dated November 20, 2026) and wire reports citing serious data integrity problems in Capricor’s pivotal clinical trial.

Within minutes, biotech short-seller Martin Shkreli (@MartinShkreli) seized on the FDA’s public rebuke in two back-to-back X posts (4:14 PM PT and 4:20 PM PT, November 20, 2026):

“FDA statement on $CAPR is nearly unprecedented. We must send the message via the @USDOJ, which I am absolutely loathe to recommend on anyone for obvious reasons, that manipulating clinical trial data is the worst possible crime in biotech and life sciences. cc @linda_marban @AGToddBlanche” — @MartinShkreli (Nov 20, 2026)

“$SLS = $CAPR by the way” — @MartinShkreli (Nov 20, 2026, posted as shares of SELLAS Life Sciences [NASDAQ: SLS] slid -8.08% to $13.66)

Is Shkreli simply taking a victory lap on a year-old short that blew up in his face in late 2025—or did he just put his finger on an identical regulatory trap waiting to detonate inside SLS? Using the official FDA BLA 125842 Briefing Document (FDA CTGTAC Package), Capricor’s Sponsor Briefing Document (Capricor CTGTAC Package), Capricor’s Q3 2026 Form 10-Q, ClinicalTrials.gov protocols (NCT05126758, NCT03406780, NCT04229979), and SELLAS’s SEC filings, this investigation separates proven data manipulation from overstated Twitter analogies.

[!IMPORTANT] Forensic Thesis Summary:

  1. Why $CAPR Imploded -80.4% (FDA BLA 125842 Smoking Guns): The FDA didn’t reject deramiocel over a minor paperwork nitpick. In its official briefing audit, CBER documented that double-blind HOPE-3 (NCT05126758) FAILED BOTH endpoints under its prespecified SAP 1.1: upper-limb PUL 2.0 scored p = 0.24 (+0.66 pts) and cardiac LVEF scored p = 0.97 (-0.041%, placebo slightly better). Capricor then pulled biostatistics in-house in violation of its blinding plan, functionally unblinded arms via 41.5% vs. 15.4% hypersensitivity reactions, and rewrote SAP 3.0 one day before unblinding (Nov 24, 2025)—transforming p = 0.24 into p = 0.029 by altering endpoints (percent change / ranked LVEF), excluding 22% of patients from cardiac analysis, erasing Months 6–12 of an improving placebo completer, assigning the worst score in the trial to a placebo dropout while treating 3 active dropouts as missing-at-random, and breaking its own SAP 3.0 rules post-unblinding.
  2. Why $1.49 ($86.6M) Still Isn’t “Cheap Cash”: Although Capricor held $197.6 million in cash and marketable securities (~$3.40/sh) at Sept 30, 2026, it carries $92.2 million in lease liabilities (surging from $14.5M via a pre-approval San Diego cleanroom expansion), $26.1 million in non-cancellable purchase commitments, $96.4M nine-month cash burn (~$129M/yr), a distribution dispute with Nippon Shinyaku, a Mesoblast patent suit, and multiple 2026 securities class actions.
  3. Testing "$SLS = $CAPR" (Where the Warning Bites vs. Where It Breaks): Shkreli has an unmistakable conflict of interest (burned shorting CAPR in late 2025, short SLS into its Nov 17 REGAL readout). His warning bites on regulatory fragility: both drugs go through the exact same FDA CBER / OTP division with borderline p ≈ 0.03 numbers (CAPR 0.029–0.045; SLS 0.035), 1-to-2 patient sensitivity, mid-trial SAP changes, and undisclosed raw curves. Yet "$SLS = $CAPR" is a false equivalence on the fraud charge today: SELLAS’s REGAL endpoint is hard all-cause death (OS) (not a malleable functional/MRI score), its SAP amendment (105 → 80 deaths) was filed with FDA 4 years before final lock (Oct 2022) under an independent CRO (PPD) and IDMC, and GPS beat a strong 14.7-month control arm—whereas Capricor rewrote SAP 3.0 in-house 1 day before lock after failing prespecified SAP 1.1.

1. Three Competing Narratives Around Friday Night’s Crash

Analytical Dimension Capricor & The Lancet Defense (Management Narrative) FDA CBER / OTP Forensic Audit (BLA 125842 Record) Martin Shkreli’s "$SLS = $CAPR" Contagion Thesis
Core Claim HOPE-3 hit PUL 2.0 (+54% slowing, p = 0.029, published in The Lancet July 2026) and 24-month OLE showed 76% slowing (+1.56 pts), supporting upper-limb approval. HOPE-3 failed prespecified SAP 1.1 (PUL p = 0.24, LVEF p = 0.97); Capricor breached its blinding plan, took stats in-house, and altered SAP 3.0 1 day pre-lock via 2-placebo-patient imputation tricks. Headline p ≈ 0.03 biotech press releases that squeeze short-sellers before full data release collapse -80% when FDA CBER opens the hood.
Regulatory / Legal Exposure Form FDA 483 (July 2026 BIMO) had just one SOP/vendor-oversight observation that did not affect HOPE-3 integrity; SAP 1.1 was merely an outdated draft. Post-study SAP 2.0/3.0 violated ICH E9, excluded 22% of subjects from LVEF, abandoned 2+1 MRI consensus for single-reader reads (up to 12.7% gap), and warranted a Nov 20 public integrity rejection. Calls for @USDOJ referral on CAPR while warning SLS longs that REGAL’s open-label p = 0.035 faces the same CBER guillotine.
Blind Spot Completely ignores that 3 treated withdrawals were assumed MAR while 2 placebo patients were penalized/censored to flip p from 0.21 to 0.029. None on the CAPR stats itself—though FDA did not formally vote on PUL 2.0 at July’s CTGTAC, giving bulls false hope until Friday’s Nov 20 rejection. Conflates proven in-house post-trial SAP manipulation (CAPR) with unproven statistical fragility on a hard mortality endpoint (SLS).

2. Inside FDA’s Forensic Audit: How p = 0.24 (and p = 0.97) Became p = 0.029 (and p = 0.041)

Imagine throwing 106 darts at a board, losing the match 24-to-97, and then—after the match ends and you see where the darts landed—taking scoring away from the independent referee, redefining the unit from inches to percentages, throwing out two of your opponent’s best darts, giving their absent player the lowest score in the arena while giving your own three missing players the average score of winners, and declaring a p = 0.029 victory the night before the scoreboard lights turn on.

That is not hyperbole. That is literally what the official FDA BLA 125842 Briefing Document documented across pages 8 and 26–44 ahead of the July 29, 2026 Advisory Committee (9–3 negative vote on cardiomyopathy), setting up Friday’s November 20 rejection:

How the Numbers Were Engineered (SAP 1.1 → SAP 2.0 → SAP 3.0 → Feb 2026 CSR)

  1. Breaking the Independent Blinding Plan (Oct 2023): Capricor’s approved blinding plan stipulated that “the blinded biostatistics team [at independent CRO Pentara Corporation] will develop the study Statistical Analysis plan.” Yet FDA BIMO audit trails revealed Capricor deviated from that plan, moved biostatistics and programming in-house in October 2023, and authored SAP 2.0 and SAP 3.0 itself (FDA Briefing, pp. 31–32).
  2. Functional Unblinding Before Rewriting the SAP (June 18, 2025 onward): Double-blind HOPE-3 (N = 106 randomized: 54 deramiocel, 52 placebo) completed its 12-month period on June 18, 2025, rolling patients into open-label HOPE-3-OLE. Hypersensitivity reactions hit 41.5% (22/53) of deramiocel patients versus 15.4% (8/52) of placebo patients—and 11 Year-1 placebo patients suddenly developed hypersensitivity upon receiving open-label drug in Year 2 (FDA Briefing, pp. 8, 36). Under ICH E9, rewriting endpoints after data collection and functional unblinding destroys Type I error control.
  3. Flipping PUL 2.0 (Primary Endpoint) via Two Placebo Patients (Tables 7 & 12):
    • Under prespecified SAP 1.1 (July 19, 2022)—the version used to power HOPE-3 (N = 68 planned for 1.5-point PUL 2.0 absolute change)—deramiocel failed cleanly: +0.66 points (-1.73 vs. -2.39, 95% CI: -0.45 to +1.77, p = 0.24).
    • On September 26, 2025 (SAP 2.0), Capricor switched the endpoint from absolute change to percent change from baseline (which FDA noted has no validated clinical interpretation in DMD) and imputed the worst observed value in the entire trial for 1 placebo dropout who left due to an adverse event (AE). Result: p = 0.26 raw / p = 0.08 imputed—still failed!
    • On November 24, 2025 (SAP 3.0)—one single day before November 25 database lock and unblinding, and NEVER submitted to or agreed with FDA—Capricor added a brand-new intercurrent-event rule that erased Months 6, 9, and 12 observed data from a SECOND placebo patient who had completed the study and improved on PUL 2.0, citing prohibited medication use (FDA Briefing, pp. 35, 39, 52). Meanwhile, 3 deramiocel dropouts ("withdrawal of consent", reason unknown) were treated as Missing-At-Random (MAR)—assuming they maintained full treatment benefit! Even then, SAP 3.0 failed without the 2-patient imputation (p = 0.21) and failed with only the AE dropout imputed (p = 0.085), hitting p = 0.045 (+4.16%) only when both placebo patients were penalized.
    • Finally, in the February 3, 2026 Clinical Study Report (CSR)—after formal unblinding—Capricor violated its own SAP 3.0 by retaining a "slow progressor" covariate that SAP 3.0’s own criteria mandated removing (because only 1 slow progressor existed in the treated arm vs. 5 in placebo!), pushing the headline number down to p = 0.029 (+4.55%, "54% slowing")—the number published in The Lancet on July 29, 2026!
  4. Flipping Cardiac LVEF (Key Secondary) + Dropping 22% of Patients (Tables 4, 9 & 13):
    • Under SAP 1.1, LVEF change was -0.041% (95% CI: -2.58% to +2.49%, p = 0.97)—virtually zero difference. Under SAP 2.0, it was -0.37% (p = 0.77 raw / p = 0.57 imputed).
    • In SAP 3.0 (1 day before lock), Capricor converted LVEF into ranked change (ANCOVA on ranks), discarding Month 6 reads and excluding 23 randomized patients (22% of the trial) who lacked paired baseline + Month 12 scans, violating ITT. That still failed at p = 0.09 (p = 0.22 without the 2 placebo manipulations). Only by adding an undocumented baseline-LVEF/age interaction term post-unblinding (Feb 3 CSR) did Capricor manufacture a nominal p = 0.041.
    • Worse, per Table 4 (FDA Briefing, pp. 26–27), Capricor abandoned its Cardiac MRI Charter’s 2+1 consensus review when Reader B read only 62/82 subjects (blaming an image-transfer config issue), relying solely on Reader A alone—even though Reader A and Reader B disagreed by an average of 3.20% LVEF at Month 12 (up to 12.67% at screening and 9.88% at Month 12, dwarfing the claimed treatment effect).
xychart-beta
    title "HOPE-3 Primary Endpoint (PUL 2.0) p-Value Across SAP Revisions (FDA Briefing Table 7 & 12)"
    x-axis ["SAP 1.1 Raw", "SAP 2.0 Raw", "SAP 3.0 Raw", "SAP 3.0 (1 Placebo)", "SAP 2.0 Imputed", "SAP 3.0 (2 Placebos)", "Feb 2026 CSR (Post-Lock)"]
    y-axis "Two-Sided p-Value" 0 --> 0.30
    bar [0.24, 0.26, 0.21, 0.085, 0.080, 0.045, 0.029]
xychart-beta
    title "HOPE-3 Key Secondary (LVEF) p-Value Across SAP Revisions (FDA Briefing Table 9 & 13)"
    x-axis ["SAP 1.1 Raw", "SAP 2.0 Raw", "SAP 2.0 Imputed", "SAP 1.1 Imputed", "SAP 3.0 Raw", "SAP 3.0 (2 Placebos)", "Feb 2026 CSR (Post-Lock)"]
    y-axis "Nominal p-Value" 0 --> 1.05
    bar [0.97, 0.77, 0.57, 0.42, 0.22, 0.090, 0.041]
Study Version & Date Primary PUL 2.0 Difference (95% CI) & p-Value Secondary LVEF Difference (95% CI) & p-Value Key Methodological & Data-Integrity Change Documented by FDA
SAP 1.1 (Jul 19, 2022) — Prespecified (Pentara CRO) +0.66 pts (-0.45, +1.77) | p = 0.24 -0.041% (-2.58%, +2.49%) | p = 0.97 Original MMRM absolute-change model with all available data (MAR), used to power HOPE-3. Failed both endpoints.
SAP 2.0 (Sep 26, 2025) — In-House Post-Study (Raw) +2.38% | p = 0.26 -0.37% | p = 0.77 Switched PUL 2.0 to percent change after HOPE-3 blinded phase ended (Jun 18, 2025); without imputation both endpoints failed.
SAP 2.0 (Sep 26, 2025) — With 1 Placebo Imputed +3.74% | p = 0.08 +0.74% | p = 0.57 Assigned worst observed score in the trial to 1 placebo AE dropout (PUL p = 0.08, LVEF p = 0.57). Still failed both.
SAP 3.0 (Nov 24, 2025) — 1 Day Pre-Lock (Raw / 1 PBO) Raw: +2.53% (p = 0.21); 1 PBO: +3.34% (p = 0.085) Raw: +6.88 ranks (p = 0.22); 1 PBO: +7.76 (p = 0.17) Converted LVEF to ranks excluding 23 patients (22%); still missed whenever 2nd placebo completer wasn’t erased.
SAP 3.0 (Nov 24, 2025) — Both Placebo Rules Applied +4.16% (0.09%, 8.23%) | p = 0.045 +9.51 ranks (-1.64, 20.65) | p = 0.09 Erased Months 6–12 of improving 2nd placebo completer + imputed AE dropout; kept 3 active dropouts as MAR (never agreed by FDA).
Modified SAP 3.0 (Feb 3, 2026 CSR) — Post-Unblinding +4.55% (0.47%, 8.63%) | p = 0.029 (Lancet figure) +11.65 ranks (0.47, 22.82) | p = 0.041 After unblinding, violated SAP 3.0 rules by keeping "slow progressor" covariate (n=1 treated) & added undocumented LVEF/age interaction term.

To steelman Capricor’s defense fairly using its Sponsor Briefing Document and Q3 2026 Form 10-Q: Capricor argued SAP 1.1 was an obsolete draft predating Cohort B’s San Diego manufacturing shift; that SAP 1.7 and 2.0 were sent to FDA without prior objection; that SAP 3.0 was signed Nov 24 prior to Nov 25 formal unblinding; that The Lancet independently peer-reviewed p = 0.029; and that 24-month HOPE-3-OLE placebo crossovers showed a 76% slowing (+1.56 pts, 95% CI: 0.47–2.64). Yet under ICH E9, none of that rescues a trial whose results evaporate back to p = 0.21–0.24 (PUL) and p = 0.22–0.97 (LVEF) the instant two placebo patients aren’t penalized after functional unblinding—explaining why FDA rejected the BLA on November 20 with an unusual public data-integrity rebuke.


3. Why $1.49 ($86.6M Cap) Trades Below $197.6M Gross Cash: Distress Balance-Sheet Audit

At $1.49 after hours (58,138,989 shares outstanding per Q3 2026 Form 10-Q), Capricor’s equity value is $86.6 million—less than half of its $197.58 million in cash and marketable securities ($3.40/sh). Why isn’t $1.49 a risk-free net-cash bargain? Because Capricor spent 2026 building out commercial infrastructure as if approval were guaranteed:

Balance-Sheet / Litigation Item (Q3 2026 Form 10-Q, Sept 30, 2026) Reported Primary Figure Forensic Impact at $1.49 After-Hours Share Price
Cash, Cash Equivalents & Marketable Securities $197.58M ($44.28M cash + $153.30M marketable securities; $198.5M incl. restricted cash) Gross $3.40 / share across 58.14M basic shares—creates the superficial illusion of trading at 0.44× cash.
Operating Lease Liabilities (San Diego Cleanroom Expansion) $92.23M ($1.52M current + $90.71M long-term; up 6.3× from $14.52M at Dec 31, 2025!) Commercial-scale cGMP facility expansion committed before FDA approval locks up nearly half of gross cash unless renegotiated/subleased.
Purchase Commitments & Other Balance-Sheet Liabilities $26.10M non-cancellable POs + $16.38M AP/accrued + $12.00M current deferred revenue Subtracting $92.23M leases + $16.38M AP/accrued + $26.10M POs leaves only ~$62.9M ($1.08/sh) unencumbered cash before wind-down burn!
Operating Cash Burn Rate (9M 2026) $96.43M operating cash burn in 9M 2026 ($117.33M net loss; ~$129M/yr run-rate, even after a 10% Sept 2026 layoff) At ~$129M/yr burn (~$10.7M/month), every quarter spent fighting FDA/reorganizing incinerates ~$0.50+/share of net cash.
Commercial & Legal Siege (Note 15) Distribution dispute with Nippon Shinyaku / NS Pharma; Mesoblast patent suit; 2 securities class actions (Nkamga Jul 30, Novick Sept 28); Rosen derivative suit; former-employee claims. Today’s Nov 20 integrity rejection pours gasoline on the Rule 10b-5 securities fraud suits and partner termination risk, creating severe uninsured defense/settlement overhang.

4. Testing Martin Shkreli’s "$SLS = $CAPR" Thesis: Valid Warning vs. False Analogy

First, put Shkreli’s bias and track record directly on the table: he shorted $CAPR in late 2025 claiming data manipulation, got squeezed brutally when Capricor released HOPE-3’s p = 0.029 topline in December 2025 (suffering multi-million-dollar losses), and was dramatically vindicated by FDA’s November 20, 2026 integrity rejection. Simultaneously, he shorted SELLAS Life Sciences ($SLS) into its November 17, 2026 Phase 3 REGAL readout (24.0 vs. 14.7 months OS, HR = 0.59, p = 0.035), watching SLS rocket +156.4% ($7.47 → $24.89 peak) before settling at $13.66 (-8.08%) on November 20 after a $172.5M offering at $13.00.

When Shkreli posts "$SLS = $CAPR by the way", he is saying: do not trust a biotech’s headline p ≈ 0.03 press release until FDA CBER inspects the raw data, censoring, and SAP history—because CBER just incinerated a p = 0.029 stock by -80%. Here is how that comparison actually scores across seven hard structural tests:

Structural Test Capricor Deramiocel (HOPE-3, NCT05126758) SELLAS GPS (REGAL, NCT04229979) Does "$SLS = $CAPR" Hold?
1. FDA Reviewing Division & Pathway FDA CBER / OTP (single pivotal Phase 3 + 20-patient HOPE-2 supportive study). FDA CBER / OTP (single pivotal Phase 3 + 22-patient CR1 / 10-patient CR2 Phase 2 supportive studies). YES — Strong Parallel. Same strict CBER standard (21 U.S.C. § 355(d)) rejecting fragile single-trial BLAs.
2. Headline p-Value & 1–2 Patient Fragility p = 0.029–0.045; flipped to p = 0.085–0.24 by just 2 placebo patients. p = 0.035 (95% CI ~[0.36, 0.96]); flipped past 0.0416/0.050 by 1–2 shifted/censored deaths. YES — Strong Parallel. Both rest on razor-thin 1–2 patient margins.
3. Day-1 Transparency vs. Missing Data Dec 2025 PR highlighted +54%, p = 0.029 without disclosing SAP 1.1 (p = 0.24, LVEF p = 0.97) or 2-patient imputation. Nov 17, 2026 PR omitted 95% CI, KM curves, arm death/censoring counts, LFS, MRD, BAT mix, and U.S. (23.3% sites) subgroups. YES — Partial Parallel. Until SLS shows LFS & censoring tables, black-box risk persists.
4. Endpoint Objectivity Subjective motor checklist (PUL 2.0) + variable MRI (LVEF up to 12.7% inter-reader gap) — transformed post-hoc into “percent change” and “ranks”. Hard all-cause mortality (OS — alive vs. dead). Cannot be converted into "percent change" or "ranked change". NO — Major Break. Death dates cannot be subjectively re-graded; only censoring can distort OS.
5. SAP Timing & Blinding Governance Took stats in-house (Oct 2023) breaching blinding plan; rewrote SAP 3.0 after functional unblinding, 1 day before lock (Nov 24, 2025) without FDA agreement; broke own SAP 3.0 post-lock. Amended SAP (105 → 80 deaths) and submitted to FDA on Oct 14, 2022 — 4 years before final lock, overseen by external CRO (PPD) and IDMC (Jan 2025 interim pass). NO — Major Break. 4 years pre-lock with FDA/CRO/IDMC oversight ≠ 1 day pre-lock in-house rewrite.
6. Control Arm Performance Failed prespecified SAP 1.1 completely (PUL p = 0.24, LVEF -0.04% p = 0.97). Beat a robust 14.7-month control arm (nearly 3× historical 5.4 mo, matching QUAZAR 14.8 mo) by +9.3 months. NO — Major Break. REGAL did not win via a collapsing control group.
7. Institutional Capital & Balance Sheet Cash burn ~$129M/yr, $92.2M lease overhang, already hit by CRL #1 & 9–3 AdCom rejection. Just cleared $172.5M zero-warrant equity via J.P. Morgan & TD Cowen (~$296.5M pro forma cash vs. ~$30M/yr burn). NO — Major Break. SLS has ~10 years of pre-launch cash; CAPR had an AdCom loss already on record.
flowchart TD
    subgraph SG1["FDA CBER / OTP Single-Trial Evidentiary Filter"]
        F1["Gate 1: Pre-Specified SAP & Blinding Integrity"]
        F2["Gate 2: Statistical Persuasiveness & Robustness (Tipping-Point Audit)"]
        F3["Gate 3: Secondary Endpoint Concordance & Confirmatory Evidence"]
    end

    subgraph SG2["Capricor ($CAPR / HOPE-3): FAILED ALL 3 GATES -> -80.4% Crash"]
        C1["In-house SAP takeover (Oct 2023)<br/>41.5% vs 15.4% hypersensitivity unblinding<br/>SAP 3.0 written 1 day pre-lock"]
        C2["SAP 1.1 Failed (PUL p=0.24, LVEF p=0.97)<br/>Results flip on just 2 placebo subjects"]
        C3["9-3 CTGTAC Negative Vote (Jul 2026)<br/>Nov 20, 2026 Public Data-Integrity Rejection"]
    end

    subgraph SG3["SELLAS ($SLS / REGAL): PASSED GATE 1 SO FAR; GATES 2-3 PENDING"]
        S1["SAP 105 -> 80 filed Oct 2022 (4 yrs pre-lock)<br/>Hard OS endpoint; PPD CRO & Jan 2025 IDMC"]
        S2["Pending Congress Audit: p=0.035 (1-2 death fragility)<br/>Must verify censoring & open-label BAT mix"]
        S3["Pending Gate: LFS concordance, MRD, U.S. (23% sites)<br/>& 13-employee Polypeptide/PCI CMC readiness"]
    end

    F1 --> C1 --> C2 --> C3
    F1 --> S1 --> S2 --> S3

5. The Forensic Verdict: Conditional “If-Clauses” and Probability-Weighted Stance

  • If Capricor cannot unwind its $92.2M San Diego facility lease liabilities and $26.1M purchase commitments rapidly—or if DOJ/SEC inquiries escalate alongside its existing Rule 10b-5 securities class actions—then $1.49 is not a cheap “net-cash floor” ($3.40/sh gross cash will be eaten alive by ~$129M/yr burn and litigation).
  • If Capricor successfully exits its leases, slashes burn by >70%, and monetizes StealthX exosomes or foreign DMD rights, then residual net cash (~$80M–$110M) could support a restructuring bounce toward $2.00–$3.00.
  • If SELLAS’s upcoming REGAL medical conference presentation shows concordant LFS, balanced censoring (<5% arm gap), and consistent U.S. (23.3% sites) / active-BAT hazard ratios, then "$SLS = $CAPR" will be exposed as a classic Guilt-by-Association fallacy—even though $CAPR’s November 20 execution by CBER proves SLS cannot afford even minor censoring or SAP irregularities.
Ticker & Scenario Probability Structural Trajectory (2026–2028) Implied Share Value Expected Value Contribution
$CAPR Base Case: Restructure & Wind-Down 55% Deramiocel U.S. BLA functionally dead absent a new multi-year Phase 3; deep layoffs, partial lease exit, strategic alternatives / StealthX pivot slowly drain cash. $1.10 / sh ($0.75 – $1.50) $0.61 / sh
$CAPR Bear Case: Cash Trap & Legal Drain 30% $92.2M leases + $26.1M POs + Nippon Shinyaku / Mesoblast / Rule 10b-5 securities suits (plus potential regulatory probe) trap equity below residual liquidation value. $0.40 / sh ($0.15 – $0.65) $0.12 / sh
$CAPR Bull Case: Clean Lease Exit / EU Partnering 15% Capricor exits San Diego cleanroom lease cheaply (~$100M+ net cash preserved) and lands EU/Japan salvage deal or StealthX licensing milestone. $2.60 / sh ($2.00 – $3.25) $0.39 / sh
$CAPR Expected Fair Value (vs. $1.49 AH) 100% Gross cash ($3.40/sh) is offset by ~$2.32/sh in leases/POs/AP and ~$10.7M/mo burn $1.12 / sh (-24.8% vs. $1.49) $1.12 / sh
$SLS Contagion Risk Audit ("$SLS = $CAPR"?) Split Assessment 10%–15% probability of true $CAPR-style post-lock SAP/blinding fraud; ~35% probability of a different CBER CRL / confirmatory-trial demand (over p = 0.035 1–2 event fragility, open-label BAT censoring, 76.7% ex-U.S. skew, or 13-employee CMC). $12.63 / sh (EV vs. $13.66) Wait for full REGAL curves & LFS

Bottom-Line Authorial Stance

  1. Why $CAPR Crashed -80.4%: Capricor didn’t get unlucky with a picky FDA reviewer—it got caught red-handed by CBER moving the goalposts (SAP 1.1 → 2.0 → 3.0 → Feb CSR) in-house after functional unblinding and manufacturing p = 0.029 / p = 0.041 out of p = 0.24 / p = 0.97 primarily by penalizing two placebo patients and abandoning 2+1 cardiac MRI reads. At $1.49 after hours (EV ~$1.12/sh), avoid catching the falling knife until Capricor clarifies its $92.2M lease liabilities and cash preservation plan.
  2. What to Make of "$SLS = $CAPR": Do not buy Shkreli’s literal equation—HOPE-3 (in-house SAP rewrite 1 day before lock after SAP 1.1 failed) is not structurally equivalent to REGAL (4-year pre-lock SAP on hard all-cause mortality beating a 14.7-month control arm, backed by a $172.5M J.P. Morgan/TD Cowen equity raise). Yet do respect the regulatory warning inside his tweet: Friday night proved FDA CBER has zero tolerance for p ≈ 0.03 statistical gamesmanship in single-trial BLAs. Until SELLAS publishes REGAL’s Kaplan–Meier curves, LFS, censoring audit, and U.S. subgroup split, discipline means waiting for the raw numbers.

Primary Sources & Verified Citations

(Clinical trial metadata retrieved via ClinicalTrials.gov. All URLs programmatically verified HTTP 200.)

  1. FDA BLA 125842 Official Review Package (Deramiocel, July 29, 2026 CTGTAC): FDA Meeting Announcement | Official FDA Briefing Document PDF (Tables 4, 6, 7, 9, 12, 13, BIMO Audit) | Capricor Sponsor Briefing Document PDF | FDA Voting Questions PDF | FDA Presentation PDF
  2. FDA Regulatory Standard: Draft Guidance — Demonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence
  3. Capricor Therapeutics SEC Filings: Q3 2026 Form 10-Q (filed Nov 10, 2026) | Aug 24, 2026 Form 8-K (PDUFA Extension) | Jul 29, 2026 Form 8-K (AdCom 9-3 Vote)
  4. ClinicalTrials.gov Protocols: Capricor HOPE-3 (NCT05126758) | Capricor HOPE-2 (NCT03406780) | SELLAS REGAL (NCT04229979)
  5. SELLAS Life Sciences SEC Filings: Nov 17, 2026 REGAL 8-K | Nov 19, 2026 424B5 Prospectus | Nov 20, 2026 8-K Full Greenshoe | Nov 15, 2022 SAP Amendment Transcript (8-K Ex. 99.1) | Q3 2026 Form 10-Q